348 related articles for article (PubMed ID: 11359661)
21. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
22. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
23. Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals.
Touloumi G; Paparizos V; Sambatakou H; Katsarou O; Chrysos G; Kordossis T; Antoniadou A; Hatzitheodorou H; Stavrianeas N; Gargalianos P; Karafoulidou A; Lazanas M; Giamarelou H; Hatzakis A
HIV Clin Trials; 2001; 2(1):6-16. PubMed ID: 11590509
[TBL] [Abstract][Full Text] [Related]
24. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.
Wit FW; van Leeuwen R; Weverling GJ; Jurriaans S; Nauta K; Steingrover R; Schuijtemaker J; Eyssen X; Fortuin D; Weeda M; de Wolf F; Reiss P; Danner SA; Lange JM
J Infect Dis; 1999 Apr; 179(4):790-8. PubMed ID: 10068573
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
26. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
27. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
28. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
[TBL] [Abstract][Full Text] [Related]
29. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
30. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
31. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
[TBL] [Abstract][Full Text] [Related]
32. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
Deeks SG; Barbour JD; Grant RM; Martin JN
AIDS; 2002 Jan; 16(2):201-7. PubMed ID: 11807304
[TBL] [Abstract][Full Text] [Related]
33. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
[TBL] [Abstract][Full Text] [Related]
34. A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure.
Gonzalez-Serna A; Swenson LC; Watson B; Zhang W; Nohpal A; Auyeung K; Montaner JS; Harrigan PR
Clin Microbiol Infect; 2016 Dec; 22(12):1004.e9-1004.e16. PubMed ID: 27585940
[TBL] [Abstract][Full Text] [Related]
35. Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort.
Servais J; Schmit JC; Arendt V; Lambert C; Staub T; Robert I; Fontaine E; Plesséria JM; Burgy C; Kirpach P; Schneider F; Hemmer R
HIV Clin Trials; 2000; 1(2):17-24. PubMed ID: 11590494
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.
van Rossum AM; Bergshoeff AS; Fraaij PL; Hugen PW; Hartwig NG; Geelen SP; Wolfs TF; Weemaes CM; De Groot R; Burger DM
Pediatr Infect Dis J; 2002 Aug; 21(8):743-7. PubMed ID: 12192162
[TBL] [Abstract][Full Text] [Related]
37. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.
Djomand G; Roels T; Ellerbrock T; Hanson D; Diomande F; Monga B; Maurice C; Nkengasong J; Konan-Koko R; Kadio A; Wiktor S; Lackritz E; Saba J; Chorba T
AIDS; 2003 Jul; 17 Suppl 3():S5-15. PubMed ID: 14565604
[TBL] [Abstract][Full Text] [Related]
38. Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain.
Navarro J; Pérez M; Curran A; Burgos J; Feijoo M; Torrella A; Caballero E; Ocaña I; Ribera E; Crespo M; Falcó V
AIDS Patient Care STDS; 2014 Oct; 28(10):537-42. PubMed ID: 25111167
[TBL] [Abstract][Full Text] [Related]
39. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study.
Erb P; Battegay M; Zimmerli W; Rickenbach M; Egger M
Arch Intern Med; 2000 Apr; 160(8):1134-40. PubMed ID: 10789606
[TBL] [Abstract][Full Text] [Related]
40. Comparison of HIV Virologic Failure Rates Between Patients with Variable Adherence to Three Antiretroviral Regimen Types.
Gordon LL; Gharibian D; Chong K; Chun H
AIDS Patient Care STDS; 2015 Jul; 29(7):384-8. PubMed ID: 26114665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
